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Improved Survival of Patients With Melanoma Brain
Metastases in the Era of Targeted BRAF and Immune
Checkpoint Therapies
Sarah Sloot, MD1,2; Yian A. Chen, PhD3; Xiuhua Zhao, PhD3; Jamie L. Weber, MD4; Jacob J. Benedict, MD4;
James J. Mule, PhD5; Keiran S. Smalley, PhD2,6; Jeffrey S. Weber, MD, PhD7; Jonathan S. Zager, MD2,8,9;
Peter A. Forsyth, MD10,11; Vernon K. Sondak, MD2,8,9; and Geoffrey T. Gibney, MD12
BACKGROUND: The development of brain metastases is common for systemic treatment failure in patients with melanoma and has
been associated with a poor prognosis. Recent advances with BRAF and immune checkpoint therapies have led to improved patient
survival. Herein, the authors evaluated the risk of de novo brain metastases and survival among patients with melanoma brain metas-
tases (MBM) since the introduction of more effective therapies. METHODS: Patients with unresectable AJCC stage III/IV melanoma
who received first-line systemic therapy at Moffitt Cancer Center between 2000 and 2012 were identified. Data were collected
regarding patient characteristics, stage of disease, systemic therapies, MBM status/management, and overall survival (OS). The risk of
de novo MBM was calculated using a generalized estimating equation model and survival comparisons were performed using Kaplan-
Meier and Cox proportional analyses. RESULTS: A total of 610 patients were included, 243 of whom were diagnosed with MBM (40%).
Patients with MBM were younger, with a lower frequency of regional metastasis. No significant differences were noted with regard to
sex, BRAF status, or therapeutic class. The risk of de novo MBM was found to be similar among patients treated with chemotherapy,
biochemotherapy, BRAF-targeted therapy, ipilimumab, and anti-programmed cell death protein 1/programmed death-ligand 1 regi-
mens. The median OS of patients with MBM was significantly shorter when determined from the time of first regional/distant metasta-
sis but not when determined from the time of first systemic therapy. The median OS from the time of MBM diagnosis was 7.5 months,
8.5 months, and 22.7 months, respectively, for patients diagnosed from 2000 to 2008, 2009 to 2010, and 2011 to the time of last
follow-up (P5.002). CONCLUSIONS: Brain metastases remain a common source of systemic treatment failure. The OS for patients
with MBM has improved significantly. Further research into MBM prevention is needed. Cancer 2018;124:297-305. VC 2017 American
Cancer Society.
KEYWORDS: BRAF, brain metastasis, immunotherapy, melanoma, targeted therapy.
INTRODUCTION
Greater than one-third of patients with advanced melanoma will develop brain metastases during the course of their disease,
and even higher rates have been observed at the time of autopsy.1-3 Historically, the prognosis of patients with melanoma
brain metastases (MBM) has been poor, with a median overall survival (OS) ranging from 3 months to 6 months from the
time of diagnosis.1,2,4,5 Patients with solitary or oligometastatic disease amenable to surgery or stereotactic radiosurgery
(SRS) are reported to have better survival, with a reported median OS ranging from 7 months to 10 months.6 To the best of
our knowledge, there currently is no method with which to accurately predict who will develop MBM. However, various
parameters are associated with an increased risk (eg, melanoma arising from head and neck areas; ulcerated primary tumors;
elevated serum lactate dehydrogenase levels; and, possibly, molecular alterations in BRAF, NRAS, or PTEN).2,5,7,8
The brain has been a prominent site of treatment failure with systemic therapies for patients with advanced mela-
noma. In a prospective study evaluating the incidence of MBM between patients treated with the combinations of
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cisplatin, temozolomide, and interleukin 2 (IL-2) and cis-
platin, dacarbazine, and IL-2, approximately 49% of
assessable patients with melanoma developed central ner-
vous system (CNS) disease with no significant difference
noted between treatments.9 Similarly, MBM progression
has been reported as a primary recurrence site in up to
one-half of patients who initially responded to IL-2.10
These observations may be due to historically low rates of
controlling systemic disease (ie, prevention of tumor seed-
ing to the brain), as well as the poor CNS penetration and
MBM activity of many systemic therapies.11 Among che-
motherapies with modest CNS activity (eg, temozolo-
mide and fotemustine), studies have shown objective
MBM response rates ranging from 7% to 12%.12 Similar
disappointing results were observed among patients
treated with high-dose IL-2.13,14
New immune checkpoint and BRAF/MEK-targeted
therapies have demonstrated greater clinical activity in
patients with metastatic melanoma. The median OS has
now reached 2 years and longer in studies of BRAF/MEK
combination therapy and anti-programmed death-ligand 1
(PD-1) regimens.15-17 Phase 2 trials of these agents in
patients with active MBM also have demonstrated promis-
ing intracranial activity, with objective MBM response rates
as high as 22% with pembrolizumab and 31% with dabra-
fenib (BRAF V600E-mutant population).18-21 Although
these findings suggest that improved outcomes among
patients with melanoma could be due in part to a reduction
in CNS failure with enhanced extracranial disease control
and/or CNS activity, the brain has been reported to still be a
common site of treatment failure for BRAF-targeted ther-
apy.22,23 Therefore, to our knowledge, it remains unclear
whether MBM incidence rates significantly differ among
newer targeted and immune therapies compared with prior
treatment strategies and if patient survival continues to be
significantly impacted by the development ofMBM.
The primary objective of the current study was to
investigate the association between systemic therapy regi-
mens and de novo MBM development in patients with
advanced melanoma treated with chemotherapy, bioche-
motherapy, IL-2, BRAF-targeted agents, or immune
checkpoint blockade. The secondary objectives were to
compare the OS in patients with advanced melanoma
with and without brain metastases and assess prognostic
factors in patients with MBM who were treated with new
targeted and immune therapy strategies.
MATERIALS AND METHODS
The current study was a retrospective cohort study of
patients with unresectable metastatic melanoma
(cutaneous/unknown primary tumor, uveal, or of mucosal
origin) who were treated with systemic therapy at the Mof-
fitt Cancer Center in Tampa, Florida. To include a compre-
hensive sample size, patients were identified using a
combination of pharmacy treatment records, BRAF geno-
typing records, and clinical trial enrollment. Inclusion
requirements were AJCC stage III or stage IV melanoma,
the initiation of systemic therapy between 2000 and 2012
to allow for long-term follow-up, and at least 2 months of
follow-up while receiving first-line systemic therapy. Data
were collected regarding patient demographics, clinical/
pathologic data concerning the primary melanoma and sub-
sequent metastases, systemic therapy, and OS. Patients with
unknown primary tumors were added to the cutaneous
group based on recent literature unless there was a suspicion
by the treating investigator that the tumor was not cutane-
ous in origin.24,25 Patients then were divided in 3 groups
(2000-2008, 2009-2010, and from 2011 onward) based on
the introduction of targeted therapies. Between 2009 and
2010, an increasing number of checkpoint/targeted therapy
trials became available and 2011 was the year ipilimumab
and vemurafenib were approved. This also divided the
patients into approximately equal groups for statistical
analyses.
Because of the range of systemic therapies that the
patients received, both standard therapies and clinical trial
agents, 7 categories were used to represent generalized
treatment approaches available in clinical practice. These
included chemotherapy regimens (monotherapy and
combinations), biochemotherapy regimens (eg, concur-
rent cisplatin, vinblastine, dacarbazine, IL-2, and
interferon-a-2b used in Eastern Cooperative Oncology
Group study E3695 or similar),26 IL-2, ipilimumab
(allowed for combined ipilimumab plus other non-
checkpoint immunomodulators such as interferon), anti-
PD-1/programmed death-ligand 1 (PD-L1) therapies (eg,
pembrolizumab and nivolumab as monotherapy or in
combination with other nonimmune checkpoint stimuli
such as a multipeptide vaccine), and BRAF-targeted ther-
apy (selective BRAF inhibitor monotherapy, MEK inhibi-
tor monotherapy, and combination BRAF plus MEK
inhibitors). The remaining group (“Other”) contained all
regimens that did not fit exclusively into one of these cate-
gories (eg, dendritic cell vaccines, combination regimens
on protocol such as carboplatin, paclitaxel, and sorafenib
and ipilimumab and vemurafenib). This group also con-
tained a patient receiving treatment with ipilimumab and
nivolumab. The study was approved by the Institutional
Review Board of the University of South Florida. Patients
with MBM were defined as patients who developed
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MBM at any time during follow-up, regardless of preced-
ing and subsequent treatments. Patients developing
MBM before the initiation of systemic treatment were
classified as being diagnosed before the initiation date of
first systemic therapy. Patients with MBM who never
received systemic treatment during the course of their dis-
ease were not captured.
Statistical Analysis
Descriptive statistics were summarized for age, sex, pri-
mary melanoma type, BRAF status, and systemic therapy
received for all patients and classified by MBM status.
The first set of analyses focused on assessing the associa-
tion between variables of interest related to the develop-
ment of MBM. Clinical and demographic characteristics
between populations with and without MBM were com-
pared. Proportion differences between the 2 populations
were investigated using chi-square tests for categorical var-
iables. Monte Carlo-estimated P values for the exact test
were reported when 50% of the cells had expected
counts <5. The median differences between the MBM
and MBM-free populations for continuous variables (eg,
age) were compared using Wilcoxon rank-sum tests. We
then evaluated the association between treatment (coded
as the 7 categories of therapy as described above), systemic
treatment line (first-line, second-line, and third-line ther-
apies only), age at the time of first systemic treatment, and
the development of MBM using a generalized estimating
equation (GEE) model. Because patients often received
>1 line of systemic therapy, the GEE model was per-
formed to evaluate the correlation between each line of
therapy and MBM event in the same patient. Patients
with recurring MBM were censored for subsequent thera-
pies. For example, a patient who was free of MBM while
receiving ipilimumab as first-line therapy but then devel-
oped MBM during second-line therapy with a BRAF
inhibitor would have been classified as a negative event
followed by a positive event. The third-line therapy in this
patient would not have been included in the model.
OS, defined as the duration between the time of first
diagnosis of regional or distant metastatic disease to the
date of death, was evaluated in both patients with and
without MBM using the Kaplan-Meier method. Survival
differences between the 2 populations were determined
using a log-rank test. This survival analysis was repeated
using time zero as the date of first systemic therapy. Subse-
quent survival analyses were focused on the survival of
patients with MBM, which was calculated from the date
of diagnosis of MBM to the date of death. The Kaplan-
Meier method as well as univariate and multivariate Cox
proportional hazards regression models were used to
determine whether variables were associated with OS and
to obtain hazard ratios (HRs) and their 95% confidence
intervals (95% CIs). All statistical analyses were per-
formed using SAS statistical software (version 9.4; SAS




A total of 1016 patients initially were evaluated for inclu-
sion into this data set. Patients were excluded because of
there being<2 months of follow-up after the initiation of
systemic treatment (245 patients), no digital records avail-
able (116 patients), a nonmelanoma cancer diagnosis (40
patients), multiple melanoma primary tumors (which
confounded start dates; 4 patients) and a missing date of
diagnosis (1 patient). A total of 610 patients were
included in the database (see Supporting Information
Fig. 1). The median follow-up was 27.6 months from the
time of first regional or distant metastasis.
Of the 610 patients included in the data set, 243
patients (39.8%) developed MBM. The median time
from the initial melanoma diagnosis to the first diagnosis
of MBM was 29.6 months (range, 0-320.2 months).
Patients with MBM were significantly younger than
patients without MBM at the date of first metastasis
(median age, 58 years vs 62 years; P.0001) (Table 1).
There was a significant difference in the primary mela-
noma subtypes between patients with MBM and those
without MBM (P5 .02) (Table 1), which was largely
driven by the low number of patients with MBM with a
mucosal primary site (P5 .008). In addition, patients in
the MBM population were less likely to have regional
metastasis (stage III) as the first site of metastasis
(P< .0001). Otherwise, there were no significant differ-
ences noted with regard to sex, BRAF status, or class of sys-
temic treatments received between the patients with and
withoutMBM.
The first MBM event was most often diagnosed early
in the disease (ie, before systemic therapy [31.7%] or dur-
ing first-line treatment [35.4%]), as shown in Supporting
Information Table 1. Neurologic symptoms were present
in 53.5% of patients at the time of MBM diagnosis. Kar-
nofsky performance status (KPS) was >70% in 59.7% of
patients. The majority of patients (48.1%) had 1 MBM at
the time of diagnosis, 34.6% had 2 to 4 MBM at the time
of diagnosis and 16.5% of patients had 5 MBM and/or
leptomeningeal disease. The most frequent treatment for
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primary MBM was SRS in 118 patients (48.6%), followed
by whole-brain radiotherapy (WBRT) in 38 patients
(15.6%), craniotomy in 37 patients (15.2%), start of new
systemic treatment in 3 patients (1.2%), and continuation
of prior systemic treatment in 2 patients (1.0%). Of the
243 patients with MBM, 13 (5.4%) received no treatment.
The remainder of patients received combination treatments
such as SRS plusWBRT.








Median age (range), ya 60 (15-92) 58 (15-86) 62 (19-92) <.0001
Male sex, no. (%) 400 (65.6%) 159 (65.4%) 241 (65.7%) 1.0
Primary melanoma type, no. (%) .02
Cutaneous 583 (95.6%) 239 (98.4%) 344 (93.7%)
Mucosal 19 (3.1%) 2 (0.8%) 17 (4.6%)
Ocular 6 (1.0%) 2 (0.8%) 4 (1.1%)
Other 2 (0.3%) 0 (0.0%) 2 (0.5%)
AJCC Stage of disease at first metastasis, no. (%) <.0001
III 274 (44.9%) 82 (33.7%) 190 (51.8%)
IV 336 (55.1%) 161 (66.3%) 177 (48.2%)
BRAF status .4
BRAF V600 mutant 120 (19.7%) 54 (22.2%) 66 (18.0%)
BRAF V600 wild-type 159 (26.1%) 61 (25.1%) 98 (26.7%)
Unknown 331 (54.3%) 128 (52.7%) 203 (55.3%)
Class of systemic therapiesb .5 .5 .7 1.0
BRAF pathway inhibitor 90 (14.8%) 39 (16.0%) 51 (13.9%)
Interleukin-2 80 (13.1%) 35 (14.4%) 45 (12.3%)
Anti-CTLA-4 188(30.8%) 77 (31.7%) 111 (30.2%)
Anti-PD-1/PD-L1 therapy 50 (8.2%) 20 (8.2%) 30 (8.2%)
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen 4; MBM, melanoma brain metastases; PD-1, programmed cell death protein 1; PD-L1, programmed
death-ligand 1.
a Age at the date of first regional or distant metastasis.
bOnly first-line through third-line therapies.
Figure 1. Forest plot of odds of the risk of developing de novo melanoma brain metastases (MBM) during systemic therapy. Odds
ratio (OR) of developing de novo MBM with each class of therapy was determined using chemotherapy (chemo) as the denomi-
nator. 95% confidence intervals were reported. IL-2 indicates interleukin-2; LCI, lower confidence interval; NOS, not otherwise
specified; PD1, programmed cell death protein 1; PDL1, programmed death-ligand 1; UCI, upper confidence interval.
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Development of De Novo MBMs During the
Administration of Systemic Therapy
The association between patient age, line of systemic ther-
apy, and class of systemic therapy (first-line through
third-line only) and the de novo MBM incidence rates
were investigated using a GEE model to account for mul-
tiple lines of treatment received by the same patient.
Patients with recurring MBM were censored for subse-
quent therapies. Although there was a trend toward an
association between age and risk of developing de novo
MBM (P5 .08), no association was demonstrated
between the line of therapy or class of systemic therapy
and the risk of developing de novo MBM (P5 .68 and
.85, respectively). With regard to the latter using
chemotherapy as the reference group, the odds ratios for
developing de novo MBM were 1.5 (95% CI, 0.70-3.02)
with biochemotherapy, 1.1 (95% CI, 0.60-1.99) with ipi-
limumab, 1.0 (95% CI, 0.40-2.83) with anti-PD-1/anti-
PD-L1, and 1.3 (95% CI, 0.60-2.49) with BRAF-
targeted therapy (Fig. 1).
Overall Survival
OS, defined as the duration from the date of first metasta-
sis to death, was evaluated by Kaplan-Meier analysis for
all patients (Fig. 2A). The median OS for all patients was
30.9 months (95%CI, 28.2-36.4 months). Survival prob-
abilities at 1 year, 2 years, and 3 years were 79.7% (95%
CI, 76.3%-82.8%), 60.6% (95% CI, 56.3%-64.6%),
Figure 2. Overall survival (OS) from the date of first regional
or distant metastasis to death. (A) OS for all patients. (B) OS
for patients diagnosed with melanoma brain metastases
(MBM) compared with those with no MBM diagnosis during
the course of the disease. Tick marks represent patient cen-
soring. 95% CI indicates 95% confidence interval.
Figure 3. Overall survival (OS) of patients with melanoma
brain metastases (MBM) from the date of first MBM diagnosis
to death. (A) OS for all patients with MBM. Survival at 12, 24,
and 36 months was 43.4% (95% confidence interval [95% CI],
36.6%-50.1%), 27.3% (95% CI, 20.5%-34.4%), and 17.5% (95%
CI, 11.3%-24.9%), respectively. (B) OS for patients with MBM
by year group of MBM diagnosis. NA indicates not available.
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and 45.9% (95% CI, 41.4%-50.3%), respectively. OS
was significantly different between patients with and those
withoutMBM (medianOS: 25.9 months vs 35.5 months,
respectively [P5 .048]) (Fig. 2B). The 3-year OS rates
were 40.2% (95% CI, 33.3%-47.0%) for patients with
MBM and 49.8% (95% CI, 43.9%-55.5%) for patients
without MBM. Because fewer patients with an MBM
diagnosis had regional disease as their first metastasis, OS
also was evaluated from the time of the initiation of first
systemic therapy to death for further characterization (see
Supporting Information Fig. 2). The median OS from
the date of first systemic therapy was 20.3 months (95%
CI, 16.9-24.9 months) for patients without MBM and
14.7 months (95% CI, 13.0-21.5 months) for patients
withMBM (P5 .1755).
Data then were analyzed separately in the MBM
cohort. The median OS from the date of MBM diagnosis
to the date of death was 10.5 months (95% CI, 8.6-12.8
months) (Fig. 3A). Survival probabilities at 1 year, 2 years,
and 3 years were 43.4% (95% CI, 36.6%-50.1%), 27.3%
(95% CI, 20.5%-34.4%), and 17.5% (95% CI, 11.3%-
24.9%), respectively.
Prognostic Factors for Patients With MBM
Variables previously identified as being associated with
MBM prognosis were evaluated by Kaplan-Meier analysis
(using survival from the date of MBM diagnosis to death).
These included age, sex, BRAF V600 mutation status,
number of MBM, neurologic symptoms, KPS,
Diagnosis-Specific Graded Prognostic Assessment (DS-
GPA), and primary type of MBM management (see Sup-
porting Information Table 1). MBM year of diagnosis
and line of therapy administered when MBM first devel-
oped were included in the analysis as well. Of these
factors, longer OS was associated with a later year of
MBM diagnosis (2011-present), fewer MBM (1 or 2-4
MBM), the absence of neurologic symptoms, primary
treatment of MBM (SRS or craniotomy), and better KPS/
DS-GPA scores (all P< .05) (see Supporting Information
Table 2). In particular, the median OS was 22.7 months
in patients who were diagnosed with MBM in 2011 or
later, compared with 8.5 months and 7.5 months, respec-
tively, for patients diagnosed with MBM between 2009
and 2010 and 2000 and 2008 (P5 .0002) (Fig. 3B).
Similar findings were observed using a univariate
Cox model to study variables associated with the risk of
death in patients with MBM (see Supporting Information
Table 3). Statistically significant variables (MBM year of
diagnosis, number of MBM, neurologic symptoms, KPS,
and primary MBM treatment) then were analyzed using a
multivariate Cox model (Table 2). DS-GPA was not
included because it incorporates both the number of
MBM and KPS. All variables demonstrated statistically
significant independent associations with risk of death.
The risk of death was 2.8-fold and 2.0-fold greater,
respectively, for patients diagnosed with MBM between
2009 and 2010 and 2000 and 2008 when compared with
those diagnosed between 2011 to the time of last follow-
up. HRs for risk of death in patients with 2 to 4 MBM
and 5 MBM and/or leptomeningeal disease were 1.5
and 2.0, respectively, compared with for patients with 1
MBM. Patients with neurologic symptoms had an HR of
2.0 compared with asymptomatic patients with MBM.
Although a KPS of70 had an HR of 2.4 compared with
a KPS >90 to 100, there was no significant difference
noted between a KPS of 70 to 90 and a KPS of >90 to
100. Receipt of BRAF-targeted therapy and/or immune
checkpoint therapy was analyzed to determine the
TABLE 2. Multivariate Cox Model for MBM Prognostic Factors
Parameter Comparison HR (95% CI) P
MBM y of diagnosis 2008 vs 2011-present 1.98 (1.10-3.56) .0226
2009-2010 vs 2011-present 2.77(1.58-4.87) .0004
No. of MBM 2-4 vs 1 1.52 (0.92-2.52) .1038
5 or leptomeningeal vs 1 1.95 (1.04-3.66) .0374
Neurologic symptoms Yes vs no 1.95 (1.16-3.30) .0123
MBM line of systemic therapy 1/1-2 vs 0 (before systemic therapy) 1.20 (0.71-2.04) .4999
2/2-3 vs 0 (before systemic therapy) 4.72 (2.55-8.72) <.0001
3 vs 0 (before systemic therapy) 1.64 (0.86-3.12) .1310
MBM primary treatment None vs SRS 2.66 (1.13-6.25) .0254
Surgery vs SRS 1.50 (0.77-2.94) .2312
WBRT vs SRS 0.98 (0.54-1.75) .9309
KPS 70 vs> 90-100 2.41 (1.19-4.86) .0142
>70-90 vs> 90-100 1.08 (0.65-1.78) .7708
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio; KPS, Karnofsky performance status; MBM, melanoma brain metastases; SRS, stereotactic
radiosurgery; WBRT, whole-brain radiotherapy.
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association with MBM year of diagnosis for contribution
toward improved OS. The majority of patients (72%)
who received 1 of these therapies were diagnosed with
their first MBM in 2011 or after (chi-square, 92.13;
P< .0001). Furthermore, receipt of BRAF-targeted ther-
apy and/or immune checkpoint therapy was found to be
associated with improved OS using a multivariate Cox
model (see Supporting Information Table 4). However,
the significance was diminished when both MBM year of
diagnosis and type of therapy received were included in
the model (data not shown).
DISCUSSION
In the current retrospective study, MBM incidence and
MBM patient survival were investigated and compared
with outcomes of patients with advanced stage disease
without MBM. To the best of our knowledge, this
resulted in one of the largest MBM cohorts reported to
date with the inclusion of patients receiving approved
BRAF-targeted and immune checkpoint therapy. The fol-
lowing key observations were made: 1) the overall inci-
dence of de novo MBM in patients with advanced
melanoma who were receiving systemic therapy was 40%,
which primarily occurred before or during the first line of
therapy; 2) the incidence of MBM was not significantly
different with BRAF-targeted agents, ipilimumab, or
anti-PD-1/PD-L1 therapy compared with traditional che-
motherapy; 3) the median OS of patients with MBM was
statistically shorter than that of patients without MBM
from the time of first regional or distant metastasis but
not from the initiation of first-line systemic therapy; and
4) the median OS of patients with MBMwas significantly
longer in patients diagnosed with MBM in 2011 or after,
which was independent of other MBM prognostic factors.
TheMBM incidence rate in the current study is con-
sistent with past studies in which 44% of patients with
melanoma with unresectable stage III/IV disease devel-
oped MBM.1,27 In addition, the lack of an association
between BRAF status and MBM incidence was similar to
that of several prior retrospective studies.5,8,27 However,
BRAF status was unknown in approximately 37% of the
patients in current study due to BRAF testing not being
routinely conducted before the approval of vemurafenib
in 2011, which may have impacted the results. With
regard to the timing of de novoMBM, patients were most
likely to be diagnosed before or during the first line of sys-
temic therapy (27% of all patients). This supports
National Comprehensive Cancer Network recommenda-
tions for the inclusion of brain imaging for the initial stag-
ing and monitoring of patients with advanced
melanoma.28 The fact that patients still were diagnosed
frequently with de novo MBM during second-line ther-
apy and after also supports the need for continued surveil-
lance in patients undergoing therapy; however, to the best
of our knowledge, the frequency with which to screen for
MBM is not well defined.
Contrary to what may have been expected, the rate
of de novo MBM was not found to be significantly lower
in patients treated with newer targeted and immunother-
apy agents that demonstrate objective CNS antitumor
activity.18-21 For selective BRAF inhibitors, limited drug
penetration across the blood-brain barrier and possible
brain-derived factors produced from astrocytes that
enhance tumor survival may be contributing factors.29,30
In a similar fashion, the CNS has been described as an
immune privileged site in which direct stimulation or
recruitment of cytotoxic T-cell populations may be less
robust compared with extracranial tumor sites treated
with immunotherapy.31 Another possibility is that neither
class of therapies directly target the biology underlying
brain tropism for some melanoma tumors.7,32
Encouragingly, the median OS of patients with
MBM in the current data set appears much improved
compared with historical data. Davies et al reported a
median OS of 4.7 months after a diagnosis of MBM in
patients who developedMBM during clinical trial partici-
pation between 1986 and 2004.1 In the current study, the
median OS was 10.5 months from the time of MBM
diagnosis for the entire MBM patient population, which
was driven largely by substantially improved survival
observed in patients diagnosed in 2011 or after (median,
22.7 months for this patient population). The results of
the current study are supported by multiple smaller retro-
spective studies in which the median survival for patients
with MBM treated with SRS and either BRAF therapies
or immune checkpoint therapy has been 1 to 2 years.33-40
More important, the gap in OS between patients with and
without MBM appears to be narrowing and was not
found to be statistically significant in the current study
when determined from the time of first systemic therapy.
The current study has several limitations. By identi-
fying patients largely based on systemic therapy records,
patients with MBM who never received systemic treat-
ment due to cure by craniotomy or SRS or death occur-
ring before therapy were not captured. The exclusion of
patients with<2 months of follow-up while receiving sys-
temic therapy might have added to this latter bias, causing
an overestimation of OS. However, this type of bias is pre-
sent in other published studies (eg, Davies et al1). Another
limitation is the potential variability of surveillance brain
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imaging. Many of the patients receiving BRAF-targeted
and immune checkpoint therapies participated in clinical
trials in which brain imaging routinely was performed
and could have introduced a lead time bias. Inevitably,
bias arises from separating treatments out by line of ther-
apy. Current cancer care has become increasingly complex
and many patients with MBM receive a combination of
therapies, both brain-directed therapies such as WBRT/
SRS and systemic therapies. Last, the focus of the current
study was on the development of de novo MBM during
systemic therapy. Tracking progression in treated patients
with MBM and the development of subsequent MBM
was beyond the scope of this investigation.
The development of brain metastases remains a clin-
ical problem despite better OS in patients diagnosed since
the introduction of BRAF-targeted and immune check-
point therapies. This is in part reflective of the major
advances in treating extracranial disease and more effec-
tive localized MBM control with craniotomy and SRS.
The exclusion of patients with treated MBM from clinical
trials is not appropriate given the more favorable survival
of patients with MBM. Future research concerning strate-
gies to abrogate the development of MBM is warranted.
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